Development and characterization of a live varicella vaccine (Oka strain).
A live varicella vaccine (Oka strain) was developed by serial passage of the Oka strain isolated in our laboratory, in human embryonic lung cells (11 times at 34 C) and guinea pig embryo cells (12 times at 37 C). It is slightly temperature sensitive at 39 C and shows a higher ratio of infectivity in guinea pig embryo cells to infectivity in human embryo cells than wild-type strains. The DNA digest with Hpa I enzyme of the Oka strain contained one unique fragment (K), although its mobility differed only slightly from that of the corresponding fragment of wild-type strains. Studies with clinical varicella zoster virus (VZV) isolates from vaccinees indicated that tests on the ratio of infectivity in guinea pig embryo fibroblasts (GPEF) to that in human embryo fibroblasts (HuEF) and the profile of the DNA digest with Hpa I are useful for differentiation of the vaccine strain from wild-type strains. The vaccine virus showed stable immunogenicity during at least 15 further repeated passages in human diploid cells, a character which seems helpful for production of a large quantity of vaccine virus for practical use.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D002644:Chickenpox / Q000382:microbiology; D002675:Child, Preschool; D004279:DNA, Viral / Q000032:analysis; D006168:Guinea Pigs; D014645:Herpesvirus 3, Human / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D007120:Immunochemistry; D013696:Temperature; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines / Q000276:immunology; D014776:Virus Cultivation
D000914:Antibodies, Viral; D004279:DNA, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines